I don't think so Greggors. All we need is approval of 1/2/or-3 more indications from these gazillion indies and then go for the jugular on these wider pool non oncology indications from ponatinib and Nmole(if this Nmole turns out to be Choline Kinase inhibitor) and perhaps 113 too. Once we get unimpeded revenues from the approved drugs, ariad in my opinion is going to grow by leaps and bounds which is why I hate the thought of a buyout now, lol. In the lottery, you can have 10 lifetimes and your chances are still very nil in winning the jackpot. At some point back in time here, just maybe 2/3 years back, somebody put out a story, whether it's true or not I don't know, that one professional analyst was saying that there is one small biotech that could be worth $600 a share in the not too distant future. The author of that post did not mention the biotech company and one poster responded with irrational exuberance, not me, that it could be ariad. I know I'm giving ammunition to the naysayers here but hey, it is what it is. Perhaps somebody would remember that post too....jmo.
News 
Market Data 
Discover 
